Adagene (ADAG) Cash & Equivalents (2019 - 2026)

Adagene (ADAG) has reported Cash & Equivalents for 7 consecutive years, with $74.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 12.53% year-over-year to $74.5 million; the TTM figure through Dec 2025 stood at $74.5 million (down 12.53% YoY), while the FY2025 annual figure was $74.5 million, down 12.53% from the prior year.
• Cash & Equivalents rose to $74.5 million in Q4 2025 per ADAG's latest filing, from $62.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $208.3 million in Q2 2021 and bottomed at $128.76 in Q2 2023.
• Historically, Cash & Equivalents has averaged $95.5 million across 5 years, with a median of $90.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 100.0% — and 2024, when it surged 74303888.22%.
• Adagene's Cash & Equivalents stood at $174.4 million in 2021, then dropped by 17.57% to $143.8 million in 2022, then retreated by 23.53% to $109.9 million in 2023, then slipped by 22.5% to $85.2 million in 2024, then decreased by 12.53% to $74.5 million in 2025.
• Business Quant data shows ADAG's Cash & Equivalents at $74.5 million in Q4 2025, $62.8 million in Q2 2025, and $85.2 million in Q4 2024.